Cargando…

The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea

INTRODUCTION: Dry eye disease (DED) prevalence is estimated at 9.3% of the US adult population, although diagnosed rate is much lower. This study examined real-world incidence rates (IR) and prevalence rates (PR) of DED in adults using continuous positive airway pressure (CPAP) or nasal mask therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matossian, Cynthia, Song, Xue, Chopra, Ishveen, Sainski-Nguyen, Amy, Ogundele, Abayomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573305/
https://www.ncbi.nlm.nih.gov/pubmed/33116388
http://dx.doi.org/10.2147/OPTH.S274949
_version_ 1783597412793712640
author Matossian, Cynthia
Song, Xue
Chopra, Ishveen
Sainski-Nguyen, Amy
Ogundele, Abayomi
author_facet Matossian, Cynthia
Song, Xue
Chopra, Ishveen
Sainski-Nguyen, Amy
Ogundele, Abayomi
author_sort Matossian, Cynthia
collection PubMed
description INTRODUCTION: Dry eye disease (DED) prevalence is estimated at 9.3% of the US adult population, although diagnosed rate is much lower. This study examined real-world incidence rates (IR) and prevalence rates (PR) of DED in adults using continuous positive airway pressure (CPAP) or nasal mask therapy (NMT) devices to treat sleep apnea. METHODS: Using IBM MarketScan Commercial and Medicare Supplemental claims databases, this study identified adults with ≥1 claim of CPAP or other NMT device between January 1, 2014 and June 30, 2018, ≥1 diagnosis of sleep apnea during a 12-month pre-index period, and continuous benefit enrollment ≥12 pre- and post-index date. The date of the first CPAP or NMT device claim was considered the index date. Descriptive analyses included PR, IR, and IR per 100-person years (100PY) for the overall population and subgroups including age, sex, and baseline comorbidities. RESULTS: The 1-, 2-, and 3-year PR of DED was 6.2%, 10.0%, and 13.0%, while the IR of DED was 4.0%, 7.3%, and 10.3%, respectively. Females had a higher IR of DED compared to males: 5.8%, 10.8%, and 15.1% vs 3.0%, 5.4%, and 7.9%, respectively. DED increased with age with a 1-, 2-, and 3-year PR for patients aged 18–24 years of 2.2%, 3.4%, and 5.0% vs 17.6%, 25.8%, and 32.1% in patients aged ≥75, respectively. Overall, IR per 100PY of DED was 3.68, higher for females than males (5.51 vs 2.73). PR and IR of DED were high among patients with comorbid inflammatory or metabolic conditions. CONCLUSION: The PR and IR of DED in CPAP or NMT users were higher than the reported prevalence of DED in the general population. CPAP/NMT users who were female, older, or had comorbid inflammatory or metabolic conditions may experience a higher incidence and prevalence of DED.
format Online
Article
Text
id pubmed-7573305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75733052020-10-27 The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea Matossian, Cynthia Song, Xue Chopra, Ishveen Sainski-Nguyen, Amy Ogundele, Abayomi Clin Ophthalmol Original Research INTRODUCTION: Dry eye disease (DED) prevalence is estimated at 9.3% of the US adult population, although diagnosed rate is much lower. This study examined real-world incidence rates (IR) and prevalence rates (PR) of DED in adults using continuous positive airway pressure (CPAP) or nasal mask therapy (NMT) devices to treat sleep apnea. METHODS: Using IBM MarketScan Commercial and Medicare Supplemental claims databases, this study identified adults with ≥1 claim of CPAP or other NMT device between January 1, 2014 and June 30, 2018, ≥1 diagnosis of sleep apnea during a 12-month pre-index period, and continuous benefit enrollment ≥12 pre- and post-index date. The date of the first CPAP or NMT device claim was considered the index date. Descriptive analyses included PR, IR, and IR per 100-person years (100PY) for the overall population and subgroups including age, sex, and baseline comorbidities. RESULTS: The 1-, 2-, and 3-year PR of DED was 6.2%, 10.0%, and 13.0%, while the IR of DED was 4.0%, 7.3%, and 10.3%, respectively. Females had a higher IR of DED compared to males: 5.8%, 10.8%, and 15.1% vs 3.0%, 5.4%, and 7.9%, respectively. DED increased with age with a 1-, 2-, and 3-year PR for patients aged 18–24 years of 2.2%, 3.4%, and 5.0% vs 17.6%, 25.8%, and 32.1% in patients aged ≥75, respectively. Overall, IR per 100PY of DED was 3.68, higher for females than males (5.51 vs 2.73). PR and IR of DED were high among patients with comorbid inflammatory or metabolic conditions. CONCLUSION: The PR and IR of DED in CPAP or NMT users were higher than the reported prevalence of DED in the general population. CPAP/NMT users who were female, older, or had comorbid inflammatory or metabolic conditions may experience a higher incidence and prevalence of DED. Dove 2020-10-15 /pmc/articles/PMC7573305/ /pubmed/33116388 http://dx.doi.org/10.2147/OPTH.S274949 Text en © 2020 Matossian et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Matossian, Cynthia
Song, Xue
Chopra, Ishveen
Sainski-Nguyen, Amy
Ogundele, Abayomi
The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title_full The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title_fullStr The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title_full_unstemmed The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title_short The Prevalence and Incidence of Dry Eye Disease Among Patients Using Continuous Positive Airway Pressure or Other Nasal Mask Therapy Devices to Treat Sleep Apnea
title_sort prevalence and incidence of dry eye disease among patients using continuous positive airway pressure or other nasal mask therapy devices to treat sleep apnea
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573305/
https://www.ncbi.nlm.nih.gov/pubmed/33116388
http://dx.doi.org/10.2147/OPTH.S274949
work_keys_str_mv AT matossiancynthia theprevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT songxue theprevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT chopraishveen theprevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT sainskinguyenamy theprevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT ogundeleabayomi theprevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT matossiancynthia prevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT songxue prevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT chopraishveen prevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT sainskinguyenamy prevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea
AT ogundeleabayomi prevalenceandincidenceofdryeyediseaseamongpatientsusingcontinuouspositiveairwaypressureorothernasalmasktherapydevicestotreatsleepapnea